World health Organization (WHO) experts said today that they may recommend the use of a vaccine developed by the U.S.-based Johnson and Johnson Group in countries where the 2019 variant of coronavirus disease (COVID-19) strain is spreading.
Alejandro Cravioto, chair of WHO’s Strategic Advisory Group of Immunization Experts (SAGE), told reporters that the Johnson vaccine has been shown to be effective “in countries with high transmission rates of the variant strain.
“After reviewing the evidence, the vaccine is not only safe but also sufficiently effective to be recommended for people over 18 years of age, and there is no upper age limit.” The WHO approved the one-dose Johnson vaccine for emergency use on December 12.
In addition to the vaccine developed by Johnson, vaccines developed by Pfizer and BioNTech, as well as those developed by AstraZeneca and Oxford University, have also been approved by WHO.
Johnson Vaccine 11 was approved for use in the European Union and also obtained regulatory authorizations in the United States, Canada and Africa.
Recent Comments